HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Derek D. Muehrcke Bruce W. Lytle Delos M. Cosgrove, III Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muehrcke, D. D. Articles by Cosgrove, D. M. Search for Related Content PubMed PubMed Citation Articles by Muehrcke, D. D. Articles by Cosgrove, D. M., III

Ann Thorac Surg 1995;60:538-543
© 1995 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Surgical and Long-Term Antifungal Therapy for Fungal Prosthetic Valve Endocarditis

Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio

Background. Fungal prosthetic valve endocarditis is an uncommon but serious disease. We have developed a strategy of treatment that includes perioperative amphotericin B, radical debridement of infected tissue, reconstruction using biologic tissue when possible, and prolonged oral suppressive antifungal therapy.

Methods. We retrospectively reviewed the charts of 12 patients reoperated on for fungal prosthetic valve endocarditis involving the aortic valve (10 patients: six porcine valves, two mechanical valves, two homografts) and the mitral valve (2 patients, both porcine valves). Prosthetic valve endocarditis developed in 7 within 12 months after the first valve procedure. The organisms included Candidaspecies (9 patients), Scopulariopsis brevicaulis (1), Saccharomyces cervisiae (1), and histoplasmosis (1).

Results. At operation, all patients had prosthetic vegetations, 8 had abscesses, and 4 had sinus tracts. Seven received aortic homografts, 4 received porcine valves (two mitral), and 1 received a mechanical prosthesis. Two patients died in the hospital after prolonged illnesses (83% hospital survival). Four patients had recurrence an average of 25 months later and 3 underwent further surgical intervention. One patient had recurrence and died 17 months postoperatively. One other late death occurred 96 months after operation, and there was no evidence of recurrence. Eight patients (67%) are alive and well 51.5 +/- 61.0 months (range, 1 to 189 months) after the first redo procedure for fungal prosthetic valve endocarditis.

Conclusions. We conclude that preoperative treatment with amphotericin B, radical resection of all infected tissue, cardiac reconstruction using biologic tissue when possible, and life-long oral antifungal therapy is effective for fungal prosthetic valve endocarditis.

This article has been cited by other articles:

				P. Badiee, A. Alborzi, E. Shakiba, M. Ziyaeyan, and B. Pourabbas Molecular diagnosis of Aspergillus endocarditis after cardiac surgery J. Med. Microbiol., February 1, 2009; 58(2): 192 - 195. [Abstract] [Full Text] [PDF]

				S. C. Stamou, G. Petterson, and A. M. Gillinov Surgical Treatment of Mitral Valve Endocarditis Card. Surg. Adult, January 1, 2008; 3(2008): 1069 - 1078. [Full Text]

				M. Cuenca-Estrella, A. Gomez-Lopez, M. J. Buitrago, E. Mellado, G. Garcia-Effron, and J. L. Rodriguez-Tudela In Vitro Activities of 10 Combinations of Antifungal Agents against the Multiresistant Pathogen Scopulariopsis brevicaulis. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2248 - 2250. [Abstract] [Full Text] [PDF]

				A. Vassiloyanakopoulos, M. E. Falagas, M. Allamani, and A. Michalopoulos Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user. J. Med. Microbiol., May 1, 2006; 55(Pt 5): 635 - 638. [Abstract] [Full Text] [PDF]

				B. Mahesh, G. Angelini, M. Caputo, X. Y. Jin, and A. Bryan Prosthetic Valve Endocarditis Ann. Thorac. Surg., September 1, 2005; 80(3): 1151 - 1158. [Abstract] [Full Text] [PDF]

				I. El-Hamamsy, N. Durrleman, L.-M. Stevens, L. P. Perrault, and M. Carrier Aspergillus Endocarditis After Cardiac Surgery Ann. Thorac. Surg., July 1, 2005; 80(1): 359 - 364. [Abstract] [Full Text] [PDF]

				B. G. Leshnower and T. G. Gleason Reoperative innominate arterial, ascending aortic, and root replacement for extensive fungal endocarditis J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 941 - 942. [Full Text] [PDF]

				S. Challa, A. K. Prayaga, L. Vemu, J. Sadasivan, M. K. M. Jagarlapudi, R. Digumarti, and R. Prabhala Fungal Endocarditis: An Autopsy Study Asian Cardiovasc Thorac Ann, June 1, 2004; 12(2): 95 - 98. [Abstract] [Full Text] [PDF]

				C. Chen-Scarabelli and T. M. Scarabelli Fungal Endocarditis due to Scopulariopsis Ann Intern Med, November 4, 2003; 139(9): W-77 - W-77. [Full Text] [PDF]

				M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela Scopulariopsis brevicaulis, a Fungal Pathogen Resistant to Broad-Spectrum Antifungal Agents Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2339 - 2341. [Abstract] [Full Text] [PDF]

				C.-D. Kan, C.-Y. Luo, P.-Y. Lin, and Y.-J. Yang Native-valve endocarditis due to Candida parapsilosis Interactive CardioVascular and Thoracic Surgery, December 1, 2002; 1(2): 66 - 68. [Abstract] [Full Text] [PDF]

				L. C. Pierrotti and L. M. Baddour Fungal Endocarditis, 1995-2000 Chest, July 1, 2002; 122(1): 302 - 310. [Abstract] [Full Text] [PDF]

				E Donal, P Abgueguen, D Coisne, J P Gouello, E P McFadden, J Allal, and P Corbi Echocardiographic features of Candida species endocarditis: 12 cases and a review of published reports Heart, August 1, 2001; 86(2): 179 - 182. [Abstract] [Full Text] [PDF]

				P. A. Fedalen, C. A. Fisher, B. A. Todd, P. J. Mather, and V. P. Addonizio Early fungal endocarditis in homograft recipients Ann. Thorac. Surg., October 1, 1999; 68(4): 1410 - 1411. [Abstract] [Full Text] [PDF]